Enliven Therapeutics Q4 2020 Earnings Report
Key Takeaways
Imara Inc. reported a net loss attributable to common stockholders of $49.2 million, or $3.53 per share, for the year ended December 31, 2020. The company's cash, cash equivalents, and investments totaled $88.2 million as of December 31, 2020. Research and development expenses were $32.2 million, and general and administrative expenses were $9.5 million for the year ended December 31, 2020.
Advanced IMR-687 into global Phase 2b clinical trials for sickle cell disease and beta-thalassemia.
Reported clinical data supporting IMR-687 as a novel treatment for sickle cell disease and were granted important regulatory designations for IMR-687.
Successfully completed an initial public offering, raising gross proceeds of $86.5 million.
Expanded leadership team with the appointments of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer and Lynette Hopkinson as Senior Vice President of Regulatory.
Enliven Therapeutics
Enliven Therapeutics
Forward Guidance
Imara expects full-year 2021 research and development expenses to range between $50 million and $55 million and full-year 2021 general and administrative expenses to range between $12 million and $14 million. The company expects that its cash, cash equivalents and investments as of December 31, 2020, will be sufficient to enable it to fund its planned operations into mid-2022.
Positive Outlook
- Full-year 2021 research and development expenses will range between $50 million and $55 million.
- Full-year 2021 general and administrative expenses will range between $12 million and $14 million.
- Cash, cash equivalents and investments as of December 31, 2020, will be sufficient to enable it to fund its planned operations into mid-2022.